All roads lead to targeted diffuse large B-cell lymphoma approaches
- PMID: 35167823
- DOI: 10.1016/j.ccell.2022.01.013
All roads lead to targeted diffuse large B-cell lymphoma approaches
Abstract
Two recent reports in the New England Journal of Medicine highlight the successful application of novel targeted therapies to improve the clinical outcomes of diffuse large B-cell lymphoma (DLBCL). These findings encourage us to pursue further mechanism-based therapeutic uses to make DLBCL curable in the era of precision medicine.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.
-
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904799 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
